CEO of Hanmi Pharmaceutical Woo Jong-soo, CEO of Digital Pharm Kim Dae-jin, and vice president of KT Song Jae-ho at the launch of the trilateral business venture on Friday (Courtesy of Hanmi Pharmaceutical)

Digital Pharm, jointly invested in by KT Corp. and Hanmi Pharmaceutical Co., held an official inauguration ceremony last week, the company announced Sunday. 

Founded by Catholic University of Korea professor Kim Dai-jin last November, Digital Pharm is a subsidiary of the university's holding company. The company develops digital therapeutics and electroceuticals.

KT and Hanmi invested in Digital Pharm this April. 

As its first business, the new company will develop digital therapeutics for treating alcohol and nicotine dependency; as well as electroceuticals for treating attention deficit hyperactivity disorder (ADHD). 

The company plans to begin clinical trials for the alcohol and nicotine digital therapeutics later this year.

KT will be in charge of developing platforms for digital therapeutics and drafting business strategies. The wireless carrier will also provide its pipelines to Digital Pharm. 

Hanmi, for its part, will facilitate the new therapeutics developer’s business liaison between corporations and hospitals. It will also support Digital Pharm’s marketing and the authorization of digital medical devices. 

Write to Han-Gyeol Seon at always@hankyung.com

Jee Abbey Lee edited this article.